Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.58

-1.0%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4961)	11/20/2001 5:42:43 AM
From: scott_jiminez	Read Replies (2) of 52153

Very impressive, Peter. Not quite sure what you meant by that pseudonym comment though <v,VBG>. Ron. [A suggestion from a neuroscientist: keep up with the NSAID/COX-2 inhibitors <-> neurodegenerative disease story. The McGeer's original longitudinal study finding attenuated disease subsequent to extended NSAID treatment is gaining support on a fairly broad front. Demographics suggest a significant reward for additional applications and/or novel discoveries in this field. Extreme caution must be exercised, however, in extrapolating peripheral (i.e. non-CNS) data to degenerative (or demyelinating) diseases of the brain.]

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next